CCL2 and crescentic glomerulonephritis: More interestingly, evidence for a potential functional interaction between CCL2 and AngII cognate receptors (CCR2 and AT1 receptor, respectively) has only recently emerged, with studies using specific antagonists showing that the combined blockade of the two receptors markedly attenuates renal injury (crescentic glomerulonephritis) [12] and ischemic brain damage [13].